scFv(CD20)-CD28-OX40-CD3zeta CAR-T Lentivirus

Chimeric Antigen Receptor T-cell (CAR-T) therapy is an innovative form of immunotherapy that harnesses the power of a patient’s own T-cells to fight cancer. This approach involves the genetic modification of T-cells to express a synthetic receptor, known as a CAR, which can specifically recognize and bind to antigens present on the surface of cancer cells. The engineered T-cells are expanded in vitro and infused back into the patient, where they seek out and destroy tumor cells. CAR-T therapy has demonstrated remarkable success in hematological malignancies, particularly in treating conditions like acute lymphoblastic leukemia (ALL) and certain types of lymphoma. The efficacy of CAR-T therapy can be significantly influenced by the choice of the target antigen, the co-stimulatory domains included in the CAR construct, and the cytokine milieu in which T-cells operate. Among the various platforms for CAR production, lentiviral vectors have emerged as a valuable tool due to their ability to integrate into the host genome, providing stable expression of the CAR and promoting long-term persistence of the engineered T-cells.

The scFv(CD20)-CD28-OX40-CD3zeta CAR-T lentivirus is a sophisticated construct designed to target CD20, a well-characterized antigen overexpressed in various B-cell malignancies, including non-Hodgkin lymphoma and chronic lymphocytic leukemia. In this construct, the single-chain variable fragment (scFv) derived from a monoclonal antibody specifically recognizes CD20, enabling the T-cells to selectively target and eliminate B-cells expressing this antigen. The inclusion of the CD28 and OX40 co-stimulatory domains in the CAR enhances T-cell activation, proliferation, and survival upon antigen encounter, thereby improving the overall anti-tumor response. CD3zeta serves as the signaling domain that triggers T-cell activation upon successful binding of the CAR to its target. This combination of components ensures a robust immune response against CD20-positive tumors, potentially leading to superior clinical outcomes.